Results 101 to 110 of about 31,601 (273)

Impact of adalimumab treatment on impairment of non‐professional activities in psoriasis patients

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Psoriasis can result in reduced quality of life, work productivity loss, and a significant restriction in non‐professional activities. This study investigates the effects of long‐term treatment with adalimumab regarding work ability, non‐professional activities, and health‐related quality of life in a large real‐word ...
Georgios Kokolakis, Sandra Philipp, Thomas Mosch, Björn Fritz, Robert Sabat   +4 more
wiley   +1 more source

Has The Era Of Slow Growth For Prescription Drug Spending Ended? [PDF]

, 2016
In the period 2005–13 the US prescription drug market grew at an average annual pace of only 1.8 percent in real terms on an invoice price basis (that is, in constant dollars and before manufacturers’ rebates and discounts). But the growth rate increased
Aitken, M., Berndt, Ernst R, Cutler, D., Kleinrock, M., Maini, L.   +4 more
core   +1 more source

Making Advanced Therapies Affordable and Accessible: Two Strategic Approaches

Developing World Bioethics, EarlyView.
ABSTRACT This article explores two complementary strategies for addressing the affordability and access challenges facing advanced therapies. As high development costs and limited market access have led to the withdrawal of several therapies, the article examines how these barriers create ‘valleys of death’ that prevent innovation from reaching ...
Ubaka Ogbogu, Lauren Albrecht
wiley   +1 more source

Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump [PDF]

, 2018
James Thrasher, Howard K. Surks, Irene Nowotny, Suzanne Pierre, Baerbel Rotthaeuser, Karin Wernicke‐Panten, Satish K. Garg   +6 more
openalex   +1 more source

French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025

Journal of the European Academy of Dermatology and Venereology, EarlyView.
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault, Emilie Brenaut, Marie‐Emeline Marniquet, Carla Berthault, Lea Canoen, Clarisse Marcombes, Audrey Melin, Raphaël Ouakrat, Julie Charles, Stephane Mouret, Olivier Potie, Laetitia Penso, Laura Pina Vegas, Guillaume Larid, Marine Roux, Colombe Bougeard, Sandy Sylvain, Clara Labonne, Tania Randriamiarana, Da Hee Pitaud, Floriane Etheve, Jeremy Gottlieb, Laurie Gouillon, Marine Chastagner, Emilie Sbidian, Hélène Aubert, on behalf of the Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), Hélène Aubert, Marie Masson Regnault, Emilie Brenaut, Emilie Sbidian, Laura Pina Vegas, Laetitia Penso, Jeremy Gottlieb, Marine Roux, Clara Labonne, Tania Randriamiarana, Floriane Etheve, Da Hee Pitaud, Marie‐Emeline Marniquet, Carla Berthault, Clarisse Marcombes, Audrey Melin, Colombe Bougeard, Julie Charles, Olivier Potie, Léa Canoen, Laurie Gouillon, Marine Chastagner, Sandy Sylvain, Guillaume Larid, Raphaël Ouakrat   +51 more
wiley   +1 more source

Long-Term Efficacy and Safety in Patients With Rheumatoid Arthritis Continuing on SB4 or Switching From Reference Etanercept to SB4 [PDF]

, 2017
Objectives: SB4 (Benepali, Brenzys) is a biosimilar of reference etanercept (ETN). In a randomised, double-blind, 52-week study, SB4 demonstrated comparable efficacy and safety to ETN in patients with rheumatoid arthritis (RA).
Anna Sylwestrzak, Barbara Stasiuk, Cho, Dore, Emery, Emery, Glintborg, Glintborg, Jeehoon Ghil, Jiří Vencovský, Joanna Hilt, Jørgensen, Keystone, Klareskog, Lee, Park, Paul Emery, Piotr Leszczyński, Sampson, Scott, Soo Yeon Cheong, van der Heijde, van der Heijde, Vencovsky, Weinblatt, Wieslawa Porawska, Yoo, Zdenka Mosterova   +27 more
core   +1 more source

Availability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 535-544, February 2026.
Introduction Bevacizumab, a vascular endothelial growth factor inhibitor, is used off‐label for treatment of severe anaemia related to epistaxis, gastrointestinal bleeding and/or severe hepatic arteriovenous malformations (HAVM) and right‐sided cardiac failure in patients with hereditary haemorrhagic telangiectasia (HHT).
Pernille D. Haahr, Anette D. Kjeldsen, Annette D. Fialla, Anne‐Emmanuelle Fargeton, Alexandre Guilhem, Elisabetta Buscarini, Freya Droege, Guido Manfredi, Hans‐Jurgen Mager, Jean‐Christophe Saurin, Jens Kjeldsen, Josefien Hessels, Marco C. Post, Robert Mandic, Sanne Boerman, Stefan Kasper‐Virchow, Sören Möller, Urban Geisthoff, Sophie Dupuis‐Girod   +18 more
wiley   +1 more source

Glycosimilarity assessment of biotherapeutics 1: quantitative comparison of the N-glycosylation of the innovator and a biosimilar version of etanercept [PDF]

, 2018
K
Borza, Beáta, Guttman, András, Hajba, László, Szekrényes, Ákos, Szigeti, Márton   +4 more
core  

Bispecific Antibodies Versus Chimeric Antigen Receptor T‐Cell Therapy in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Comparative Narrative Review of Efficacy, Safety, and Accessibility

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Introduction Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin lymphoma, and despite advances in frontline therapies such as rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone, approximately 30%–40% of patients develop relapsed or refractory (
Dana Sofian Abou, Husna Irfan Thalib, Fayza Akil, Samia Zuhair Sabbagh, Hala Sofian Abou, Mable Pereira, Fatma ElSayed Hassan   +6 more
wiley   +1 more source

Ten years of biosimilars in Europe: development and evolution of the regulatory pathways

Drug Design, Development and Therapy, 2017
Martin Schiestl,1 Markus Zabransky,2 Fritz Sörgel3,4 1Sandoz GmbH, Kundl, Austria; 2Sandoz Biopharmaceuticals, Hexal AG, Holzkirchen, Germany; 3Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, Germany; 4Institute of ...
Schiestl M, Zabransky M, Sörgel F
doaj